Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 304

1.

Myoma Imaging by Gynecologic Surgeons Training in Intraoperative Ultrasound Technique.

Bent RE, Wilson MD, Jacoby VL, Varon S, Parvataneni R, Saberi N, Waetjen LE.

J Minim Invasive Gynecol. 2018 Nov 29. pii: S1553-4650(18)31356-6. doi: 10.1016/j.jmig.2018.11.006. [Epub ahead of print]

PMID:
30502500
2.

Misdiagnosis of Leiomyosarcoma after Radiofrequency Ablation of Uterine Myomas.

Varon S, Parvataneni R, Waetjen E, Dunn K, Jacoby VL.

J Minim Invasive Gynecol. 2019 Mar - Apr;26(3):564-566. doi: 10.1016/j.jmig.2018.08.004. Epub 2018 Aug 17.

PMID:
30121386
3.

FGF4 retrogene on CFA12 is responsible for chondrodystrophy and intervertebral disc disease in dogs.

Brown EA, Dickinson PJ, Mansour T, Sturges BK, Aguilar M, Young AE, Korff C, Lind J, Ettinger CL, Varon S, Pollard R, Brown CT, Raudsepp T, Bannasch DL.

Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):11476-11481. doi: 10.1073/pnas.1709082114. Epub 2017 Oct 11.

4.

Family Impact of Migraine: Development of the Impact of Migraine on Partners and Adolescent Children (IMPAC) Scale.

Lipton RB, Buse DC, Adams AM, Varon SF, Fanning KM, Reed ML.

Headache. 2017 Apr;57(4):570-585. doi: 10.1111/head.13028. Epub 2017 Feb 10.

5.

Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis.

Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P, Hansen RN, Devine EB.

Cephalalgia. 2017 Apr;37(5):470-485. doi: 10.1177/0333102416678382. Epub 2016 Nov 12.

6.

OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program.

Lipton RB, Rosen NL, Ailani J, DeGryse RE, Gillard PJ, Varon SF.

Cephalalgia. 2016 Aug;36(9):899-908. doi: 10.1177/0333102416652092. Epub 2016 Jun 10.

7.

Direct and Indirect Costs of Chronic and Episodic Migraine in the United States: A Web-Based Survey.

Messali A, Sanderson JC, Blumenfeld AM, Goadsby PJ, Buse DC, Varon SF, Stokes M, Lipton RB.

Headache. 2016 Feb;56(2):306-22. doi: 10.1111/head.12755. Epub 2016 Feb 1.

PMID:
26833083
8.
9.

The negative impact of spasticity on the health-related quality of life of stroke survivors: a longitudinal cohort study.

Gillard PJ, Sucharew H, Kleindorfer D, Belagaje S, Varon S, Alwell K, Moomaw CJ, Woo D, Khatri P, Flaherty ML, Adeoye O, Ferioli S, Kissela B.

Health Qual Life Outcomes. 2015 Sep 29;13:159. doi: 10.1186/s12955-015-0340-3.

10.

Obstacles to Studying Emerging Technologies.

Waetjen LE, Parvataneni R, Varon S, Saberi NS, Jacoby VL; University of California Fibroid Network.

Obstet Gynecol. 2015 Aug;126(2):391-5. doi: 10.1097/AOG.0000000000000914.

PMID:
26241430
11.

Validation of a New Patient-Reported Outcome Measure for Facial Acne: The Acne Symptom and Impact Scale (ASIS).

Hudgens S, Harper JC, Daniels SR, Banderas B, Varon S, Alexis AF.

J Drugs Dermatol. 2015 Jun;14(6):552-9.

PMID:
26091379
12.

Improving the detection of chronic migraine: Development and validation of Identify Chronic Migraine (ID-CM).

Lipton RB, Serrano D, Buse DC, Pavlovic JM, Blumenfeld AM, Dodick DW, Aurora SK, Becker WJ, Diener HC, Wang SJ, Vincent MB, Hindiyeh NA, Starling AJ, Gillard PJ, Varon SF, Reed ML.

Cephalalgia. 2016 Mar;36(3):203-15. doi: 10.1177/0333102415583982. Epub 2015 May 22.

13.

Analogs of natural aminoacyl-tRNA synthetase inhibitors clear malaria in vivo.

Novoa EM, Camacho N, Tor A, Wilkinson B, Moss S, Marín-García P, Azcárate IG, Bautista JM, Mirando AC, Francklyn CS, Varon S, Royo M, Cortés A, Ribas de Pouplana L.

Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):E5508-17. doi: 10.1073/pnas.1405994111. Epub 2014 Dec 8.

14.

Real-world economic impact of onabotulinumtoxinA in patients with chronic migraine.

Rothrock JF, Bloudek LM, Houle TT, Andress-Rothrock D, Varon SF.

Headache. 2014 Nov-Dec;54(10):1565-73. doi: 10.1111/head.12456. Epub 2014 Oct 9.

15.

Adherence to oral migraine-preventive medications among patients with chronic migraine.

Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB.

Cephalalgia. 2015 May;35(6):478-88. doi: 10.1177/0333102414547138. Epub 2014 Aug 27.

PMID:
25164920
16.

Validation of the Headache Impact Test (HIT-6) in patients with chronic migraine.

Rendas-Baum R, Yang M, Varon SF, Bloudek LM, DeGryse RE, Kosinski M.

Health Qual Life Outcomes. 2014 Aug 1;12:117. doi: 10.1186/s12955-014-0117-0.

17.

Systematic review of migraine prophylaxis adherence and persistence.

Hepp Z, Bloudek LM, Varon SF.

J Manag Care Pharm. 2014 Jan;20(1):22-33. Review.

18.

Neurotoxicity of prion peptides mimicking the central domain of the cellular prion protein.

Vilches S, Vergara C, Nicolás O, Sanclimens G, Merino S, Varón S, Acosta GA, Albericio F, Royo M, Del Río JA, Gavín R.

PLoS One. 2013 Aug 5;8(8):e70881. doi: 10.1371/journal.pone.0070881. Print 2013.

19.

Headache-related health resource utilisation in chronic and episodic migraine across six countries.

Sanderson JC, Devine EB, Lipton RB, Bloudek LM, Varon SF, Blumenfeld AM, Goadsby PJ, Buse DC, Sullivan SD.

J Neurol Neurosurg Psychiatry. 2013 Dec;84(12):1309-17. doi: 10.1136/jnnp-2013-305197. Epub 2013 Jun 29.

20.

Adherence associated with oral medications in the treatment of spasticity.

Halpern R, Gillard P, Graham GD, Varon SF, Zorowitz RD.

PM R. 2013 Sep;5(9):747-56. doi: 10.1016/j.pmrj.2013.04.022. Epub 2013 May 3.

PMID:
23648652
21.

The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK.

Batty AJ, Hansen RN, Bloudek LM, Varon SF, Hayward EJ, Pennington BW, Lipton RB, Sullivan SD.

J Med Econ. 2013 Jul;16(7):877-87. doi: 10.3111/13696998.2013.802694. Epub 2013 May 22.

PMID:
23647483
22.

Anxiety and depression associated with caregiver burden in caregivers of stroke survivors with spasticity.

Denno MS, Gillard PJ, Graham GD, DiBonaventura MD, Goren A, Varon SF, Zorowitz R.

Arch Phys Med Rehabil. 2013 Sep;94(9):1731-6. doi: 10.1016/j.apmr.2013.03.014. Epub 2013 Mar 30.

PMID:
23548544
23.

Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II).

Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC, Varon SF, Maglinte GA, Wilcox TK, Kawata AK, Lipton RB.

Headache. 2013 Apr;53(4):644-55. doi: 10.1111/head.12055. Epub 2013 Mar 4.

PMID:
23458496
24.

Cost and predictors of lost productive time in chronic migraine and episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study.

Serrano D, Manack AN, Reed ML, Buse DC, Varon SF, Lipton RB.

Value Health. 2013 Jan-Feb;16(1):31-8. doi: 10.1016/j.jval.2012.08.2212.

25.

Cost-effectiveness of onabotulinumtoxinA for the treatment of wrist and hand disability due to upper-limb post-stroke spasticity in Scotland.

Doan QV, Gillard P, Brashear A, Halperin M, Hayward E, Varon S, Lu ZJ.

Eur J Neurol. 2013 May;20(5):773-80. doi: 10.1111/ene.12062. Epub 2012 Dec 24.

PMID:
23278954
26.

The psychometric properties of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) in chronic migraine patients.

Rendas-Baum R, Bloudek LM, Maglinte GA, Varon SF.

Qual Life Res. 2013 Jun;22(5):1123-33. doi: 10.1007/s11136-012-0230-7. Epub 2012 Jul 15.

27.

Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS).

Bloudek LM, Stokes M, Buse DC, Wilcox TK, Lipton RB, Goadsby PJ, Varon SF, Blumenfeld AM, Katsarava Z, Pascual J, Lanteri-Minet M, Cortelli P, Martelletti P.

J Headache Pain. 2012 Jul;13(5):361-78. doi: 10.1007/s10194-012-0460-7. Epub 2012 May 29.

28.

Mapping from disease-specific measures to health-state utility values in individuals with migraine.

Gillard PJ, Devine B, Varon SF, Liu L, Sullivan SD.

Value Health. 2012 May;15(3):485-94. doi: 10.1016/j.jval.2011.12.007. Epub 2012 Feb 9.

29.

Adherence with migraine prophylaxis in clinical practice.

Berger A, Bloudek LM, Varon SF, Oster G.

Pain Pract. 2012 Sep;12(7):541-9. doi: 10.1111/j.1533-2500.2012.00530.x. Epub 2012 Feb 2.

PMID:
22300068
30.

Relationship between disability and health-related quality of life and caregiver burden in patients with upper limb poststroke spasticity.

Doan QV, Brashear A, Gillard PJ, Varon SF, Vandenburgh AM, Turkel CC, Elovic EP.

PM R. 2012 Jan;4(1):4-10. doi: 10.1016/j.pmrj.2011.10.001. Epub 2011 Dec 24.

PMID:
22200567
31.

Development, reliability, and validity of a new Preference and Satisfaction Questionnaire.

Gold DT, Horne R, Coon CD, Price MA, Borenstein J, Varon SF, Satram-Hoang S, Macarios D.

Value Health. 2011 Dec;14(8):1109-16. doi: 10.1016/j.jval.2011.06.010. Epub 2011 Oct 1.

32.

Headache impact of chronic and episodic migraine: results from the American Migraine Prevalence and Prevention study.

Buse D, Manack A, Serrano D, Reed M, Varon S, Turkel C, Lipton R.

Headache. 2012 Jan;52(1):3-17. doi: 10.1111/j.1526-4610.2011.02046.x. Epub 2011 Nov 22.

PMID:
22106869
33.

OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.

Lipton RB, Varon SF, Grosberg B, McAllister PJ, Freitag F, Aurora SK, Dodick DW, Silberstein SD, Diener HC, DeGryse RE, Nolan ME, Turkel CC.

Neurology. 2011 Oct 11;77(15):1465-72. doi: 10.1212/WNL.0b013e318232ab65. Epub 2011 Sep 28.

PMID:
21956721
34.

Validating Migraine-Specific Quality of Life Questionnaire v2.1 in episodic and chronic migraine.

Bagley CL, Rendas-Baum R, Maglinte GA, Yang M, Varon SF, Lee J, Kosinski M.

Headache. 2012 Mar;52(3):409-21. doi: 10.1111/j.1526-4610.2011.01997.x. Epub 2011 Sep 19.

PMID:
21929662
35.

A case study for calculating employer costs for lost productive time in episodic migraine and chronic migraine: results of the American Migraine Prevalence and Prevention Study.

Stewart WF, Bruce C, Manack A, Buse DC, Varon SF, Lipton RB.

J Occup Environ Med. 2011 Oct;53(10):1161-71. doi: 10.1097/JOM.0b013e31822cff3c.

PMID:
21912277
36.

Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS).

Stokes M, Becker WJ, Lipton RB, Sullivan SD, Wilcox TK, Wells L, Manack A, Proskorovsky I, Gladstone J, Buse DC, Varon SF, Goadsby PJ, Blumenfeld AM.

Headache. 2011 Jul-Aug;51(7):1058-77. doi: 10.1111/j.1526-4610.2011.01945.x.

PMID:
21762134
37.

The International Burden of Migraine Study (IBMS): study design, methodology, and baseline cohort characteristics.

Payne KA, Varon SF, Kawata AK, Yeomans K, Wilcox TK, Manack A, Buse DC, Lipton RB, Goadsby PJ, Blumenfeld AM.

Cephalalgia. 2011 Jul;31(10):1116-30. doi: 10.1177/0333102411410610. Epub 2011 Jun 20.

PMID:
21690175
38.

Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine.

Yang M, Rendas-Baum R, Varon SF, Kosinski M.

Cephalalgia. 2011 Feb;31(3):357-67. doi: 10.1177/0333102410379890. Epub 2010 Sep 6.

39.

Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS).

Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A, Goadsby PJ, Lipton RB.

Cephalalgia. 2011 Feb;31(3):301-15. doi: 10.1177/0333102410381145. Epub 2010 Sep 2.

PMID:
20813784
40.

Employment and work impact of chronic migraine and episodic migraine.

Stewart WF, Wood GC, Manack A, Varon SF, Buse DC, Lipton RB.

J Occup Environ Med. 2010 Jan;52(1):8-14. doi: 10.1097/JOM.0b013e3181c1dc56.

PMID:
20042889
41.

Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass.

Kendler DL, Bessette L, Hill CD, Gold DT, Horne R, Varon SF, Borenstein J, Wang H, Man HS, Wagman RB, Siddhanti S, Macarios D, Bone HG.

Osteoporos Int. 2010 May;21(5):837-46. doi: 10.1007/s00198-009-1023-x. Epub 2009 Aug 6.

PMID:
19657689
42.

Structure-activity relationship of kahalalide F synthetic analogues.

Jiménez JC, López-Macià A, Gracia C, Varón S, Carrascal M, Caba JM, Royo M, Francesch AM, Cuevas C, Giralt E, Albericio F.

J Med Chem. 2008 Aug 28;51(16):4920-31. doi: 10.1021/jm8000828. Epub 2008 Aug 1.

PMID:
18672864
43.

Design of the POSSIBLE UStrade mark Study: postmenopausal women's compliance and persistence with osteoporosis medications.

Barrett-Connor E, Ensrud K, Tosteson AN, Varon SF, Anthony M, Daizadeh N, Wade S.

Osteoporos Int. 2009 Mar;20(3):463-72. doi: 10.1007/s00198-008-0674-3. Epub 2008 Jul 8.

PMID:
18607669
44.

Design, synthesis and antiproliferative properties of oligomers with chromophore units linked by amide backbones.

Farrera-Sinfreu J, Aviñó A, Navarro I, Aymamí J, Beteta NG, Varón S, Pérez-Tomás R, Castillo-Avila W, Eritja R, Albericio F, Royo M.

Bioorg Med Chem Lett. 2008 Apr 1;18(7):2440-4. doi: 10.1016/j.bmcl.2008.02.045. Epub 2008 Mar 5.

PMID:
18321705
45.

Costs and cost-effectiveness of adolescent compliance with treatment for latent tuberculosis infection: results from a randomized trial.

Kominski GF, Varon SF, Morisky DE, Malotte CK, Ebin VJ, Coly A, Chiao C.

J Adolesc Health. 2007 Jan;40(1):61-8. Epub 2006 Oct 27.

PMID:
17185207
46.
47.

Differentiation of rat hypothalamic dopaminergic neurons is stimulated in vitro by target cells: the melanotrophs.

Egles C, René F, Varon S, Louis JC, Félix JM, Schimchowitsch S.

Eur J Neurosci. 1998 Apr;10(4):1270-81.

PMID:
9749781
48.

Diet-induced insulin resistance precedes other aspects of the metabolic syndrome.

Barnard RJ, Roberts CK, Varon SM, Berger JJ.

J Appl Physiol (1985). 1998 Apr;84(4):1311-5.

Supplemental Content

Support Center